Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK.
Bioorg Med Chem. 2010 Jan 15;18(2):707-18. doi: 10.1016/j.bmc.2009.11.058. Epub 2009 Dec 6.
5-(Hetero)aryl-3-(4-carboxamidophenyl)-2-aminopyridine inhibitors of CHK2 were identified from high throughput screening of a kinase-focussed compound library. Rapid exploration of the hits through straightforward chemistry established structure-activity relationships and a proposed ATP-competitive binding mode which was verified by X-ray crystallography of several analogues bound to CHK2. Variation of the 5-(hetero)aryl substituent identified bicyclic dioxolane and dioxane groups which improved the affinity and the selectivity of the compounds for CHK2 versus CHK1. The 3-(4-carboxamidophenyl) substituent could be successfully replaced by acyclic omega-aminoalkylamides, which made additional polar interactions within the binding site and led to more potent inhibitors of CHK2. Compounds from this series showed activity in cell-based mechanistic assays for inhibition of CHK2.
从激酶靶向化合物库的高通量筛选中鉴定出了 CHK2 的 5-(杂芳基)-3-(4-羧酰胺基苯基)-2-氨基吡啶抑制剂。通过直接的化学方法快速探索这些苗头化合物,确定了结构-活性关系和一个假设的 ATP 竞争性结合模式,该模式通过与 CHK2 结合的几个类似物的 X 射线晶体学得到了验证。对 5-(杂芳基)取代基的改变确定了双环二氧戊烷和二氧六环基团,这提高了化合物对 CHK2 相对于 CHK1 的亲和力和选择性。3-(4-羧酰胺基苯基)取代基可以成功地被无环ω-氨基烷基酰胺取代,这在结合部位内产生了额外的极性相互作用,导致了对 CHK2 更强效的抑制剂。该系列化合物在基于细胞的机制测定中显示出对 CHK2 抑制的活性。